CA-CROWN-BIOSCIENCE
Crown Bioscience, a JSR Life Sciences company, today announces the appointment of Alex Slater as Vice President of Business Development, North America and Europe. In this role, Mr Slater will be responsible for the continued growth within the Company’s existing services portfolio and for setting the foundation for the expansion of new services.
The investment in additional leadership within CrownBio’s commercial and strategic development division reflects the increasing breadth and scientific depth of the company's offerings, and an appreciation of the need for tailored solutions at both an account and territory level. The new position will complement recent expansions in CrownBio’s Marketing, Product Management and Scientific Engagement departments, and is part of the company’s broader commitment to ensure that their customers' experience is industry-leading.
Commenting on the appointment, Mike Prosser, Senior Vice President, Commercial and Strategic Development, said, “I am delighted to welcome Alex to the team, and to fill another crucial role for the company, during an exciting phase of CrownBio’s growth. Alex’s extensive leadership experience in the CRO industry, encompassing multiple phases of drug discovery and development, will be invaluable to us as we evolve our teams in line with market opportunity.”
Mr. Slater joins CrownBio from Biocellvia, where he was VP of the business development function. In previous roles, he has served as Global VP for Business Development at Eurofins and held multiple sales leadership positions at Covance/LabCorp.
“During my interview process I was impressed by the strength of the leadership team at CrownBio, their commitment to innovation and the value they place in their customers’ experience,” commented Alex. “Further, the business development team already in place at CrownBio is highly motivated and professional and in my capacity as VP of Business Development I look forward to working with them to accelerate the organization’s future expansion.”
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Find out more at: http://www.CrownBio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005688/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blackstone Credit & Insurance Appoints Laura Coady as Global Head of CLOs and European Head of Liquid Credit Strategies3.11.2025 13:10:00 CET | Press release
Blackstone (NYSE: BX) announced today that Laura Coady, formerly Head of International Securitised Markets and Global Head of CLOs at Jefferies, has joined Blackstone Credit & Insurance (“BXCI”) as Global Head of CLOs and European Head of Liquid Credit Strategies (LCS). Based in London, Coady will oversee BXCI’s CLO activity globally, including CLO formation and investing, and lead the liquid credit business in Europe. BXCI’s LCS business manages $120 billion across corporate bonds, leveraged loans, CLOs and Multi-Asset Credit. Blackstone is the largest global manager of CLOs and loans, and the most active loan trader. The firm set a record for global annual CLO issuance in 2024, beating the previous record set by Blackstone in 2021. Dan Leiter, Head of International and Global Head of Liquid Credit Strategies for BXCI, said: “We’re thrilled to welcome Laura to further strengthen our global CLO franchise and expand our liquids business across Europe. We believe our momentum in these ar
AMINA Becomes the First Crypto Banking Group to Receive a MiCA License Through Its Austrian Subsidiary3.11.2025 13:04:00 CET | Press release
The Swiss banking group’s Austrian subsidiary is one of the first companies to be MiCAR-licensed by the Austrian FMA. Putting it in a strong position for market launch and accelerated EU expansion. AMINA Bank AG (“AMINA Bank”) today announced that its newly established subsidiary, AMINA (Austria) AG (“AMINA EU”), has received a Crypto-Asset Service Provider (CASP) license from Austria’s Financial Market Authority (FMA) under the Markets in Crypto-Assets (MiCAR) framework. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103510417/en/ AMINA Expands into the EU The FMA’s approval paves the way for AMINA EU’s launch, with regulated crypto trading, custody, and portfolio management services, as well as crypto staking, to be introduced at launch. These offerings will be available to professional investors, including family offices, corporates, financial institutions, and more. AMINA EU, an FMA-licensed crypto-asset service provi
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation3.11.2025 13:02:00 CET | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience, making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103162356/en/ TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP,
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization3.11.2025 13:00:00 CET | Press release
Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination ScheduleQDENGA is the Longest-Studied Dengue Vaccine and the Only Approved for Use Regardless of Prior Disease ExposureTakeda is Expanding Global Access to QDENGA in Partnership with National Immunization Programs, Private Payors and Public Health Coalitions, with 18.6 Million Doses Distributed in 11 Endemic Countries Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. This is consistent with its approved indications in multiple countries worldwide, which could simplify vaccination schedules and increase adherence. “We ar
SK Capital Completes Acquisition of LISI Group’s Medical Division and Launches New Platform as Precera Medical3.11.2025 12:30:00 CET | Press release
Dylan Hushka appointed Chief Executive Officer SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of LISI Group’s (Euronext: FII) Medical division (the “Transaction”). The business has relocated its headquarters to Big Lake, Minnesota and has been renamed Precera Medical (“Precera Medical” or the “Company”), marking its emergence as a leading contract development and manufacturing organization (“CDMO”) partner for blue chip medical device original equipment manufacturers (“OEMs”) and innovators. As part of the Transaction, LISI Group retained a minority stake in the Company. Precera Medical is a leading CDMO focused on the production of high-precision components and assemblies serving global medical device OEMs. The Company transforms complex designs into reliable, manufacturable solutions for the most demanding applications includ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom